SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02886195

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential treatment with EGFR-TKIs and chemotherapy in patients with EGFR(Epidermal Growth Factor Receptor)-mutant non-small-cell lung cancer (NSCLC).

NCT02886195 EGFR Gene Mutation

3 Interventions

Name: pemetrexed

Description: 500mg/m2 ivgtt d1, per three weeks
Type: Drug
Group Labels: 2

PC PC plus erlotinib

Name: cisplatin

Description: 80mg/m2 ivgtt d1, per three weeks
Type: Drug
Group Labels: 2

PC PC plus erlotinib

Name: Erlotinib

Description: 150mg po. every day
Type: Drug
Group Labels: 2

PC plus erlotinib erlotinib


Primary Outcomes

Measure: Progression-Free Survival (PFS)

Time: 6 months

Secondary Outcomes

Measure: Response Rate (RR)

Time: 2 months

Measure: Overall Survival (OS)

Time: 6 months

Description: NCI CTC 4.03

Measure: Adverse Event (AE)

Time: 2 months

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 L858R

Inclusion Criteria: - Stage Ⅳ EGFR mutation-positive NSCLC - Initial therapy - ECOG performance status 0-1 Exclusion Criteria: - EGFR mutation-negative - Previous systemic antitumour treatment Inclusion Criteria: - Stage Ⅳ EGFR mutation-positive NSCLC - Initial therapy - ECOG performance status 0-1 Exclusion Criteria: - EGFR mutation-negative - Previous systemic antitumour treatment EGFR Gene Mutation This is an open-label, randomized, parallel-group controlled clinical trial, and the study subjects recruited in this study are NSCLC patients mutant for EGFR gene (19del or L858R). --- L858R ---



HPO Nodes